Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Liposomal melatonin targets mutant hematopoiesis and bone marrow remodeling in MPN

View Full Paper
Ask AI
Bookmark
Share

Authors

SGSiddharth GuptaAMAlessandro MottaSESara Elsafy

Discussion

Loading...

Member takes

Overview

This study demonstrates therapeutic efficacy of liposomal melatonin in reducing oxidative stress and improving hematopoietic stem cell function in myeloproliferative neoplasms.

Key Points

  • This research aims to evaluate the therapeutic potency of liposomal melatonin in treating myeloproliferative neoplasms.
  • Evaluated effects of liposomal melatonin in human hematopoietic stem and progenitor cells from patients with MPN
  • Used assays including clonogenic assays and immunofluorescence to assess cellular responses
  • Investigated molecular mechanisms with techniques like gene set enrichment analysis and reactive oxygen species measurement
  • Conducted in vivo experiments in JAK2V617F mice to assess disease progression and treatment effects
  • Liposomal melatonin reduced clonogenic capacity and induced apoptosis in mutant hematopoietic stem and progenitor cells
  • Significant decrease in oxidative stress and glucose uptake in treated cells
  • In vivo findings showed reduced neoplastic parameters and improvements in bone marrow structure
  • Therapeutic combinations with ruxolitinib targeted aberrant white blood cells effectively

Cite This Study

Gupta et al. (2025) studied this question.

synapsesocial.com/papers/69362f604fa91c937236dcdchttps://doi.org/10.1182/blood-2025-1493
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Single-cell transcriptomic studies reveal altered heterogeneity in CD41 enriched megakaryocytes after targeted therapy in myeloproliferative neoplasm2025
  2. 2EP31670, a dual-BET + p300 inhibitor, demonstrates pre-clinical efficacy, including in combination with JAK inhibition, in the hMPLW515L adoptive transfer model of myelofibrosis (MF)2025 · 1 citations
  3. 3Direct small molecule inhibition of RAS enhances JAK2 inhibitor therapy in preclinical models of myeloproliferative neoplasms2025
  4. 4Disrupting a new NFkB-IL-6-JAK2-STAT cascade with novel NFkB inhibitors reduces primary myelofibrosis growth2025
  5. 5Momelotinib inhibition of JAK/STAT in a mouse JAKV617F myelofibrosis model showed concurrent activation of p-ERK and p-AKT which was reversed by combination therapy using LP-182, a novel MEK/PI3K/mTOR inhibitor2025